269 related articles for article (PubMed ID: 24892627)
21. Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy.
Gaur S; Wen Y; Song JH; Parikh NU; Mangala LS; Blessing AM; Ivan C; Wu SY; Varkaris A; Shi Y; Lopez-Berestein G; Frigo DE; Sood AK; Gallick GE
Oncotarget; 2015 Oct; 6(30):29161-77. PubMed ID: 26313360
[TBL] [Abstract][Full Text] [Related]
22. Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers.
Min K; Jo H; Song K; Cho M; Chun YS; Jon S; Kim WJ; Ban C
Biomaterials; 2011 Mar; 32(8):2124-32. PubMed ID: 21147500
[TBL] [Abstract][Full Text] [Related]
23. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery.
Cheng J; Teply BA; Sherifi I; Sung J; Luther G; Gu FX; Levy-Nissenbaum E; Radovic-Moreno AF; Langer R; Farokhzad OC
Biomaterials; 2007 Feb; 28(5):869-76. PubMed ID: 17055572
[TBL] [Abstract][Full Text] [Related]
24. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer.
Bagalkot V; Zhang L; Levy-Nissenbaum E; Jon S; Kantoff PW; Langer R; Farokhzad OC
Nano Lett; 2007 Oct; 7(10):3065-70. PubMed ID: 17854227
[TBL] [Abstract][Full Text] [Related]
25. Nanoparticle-mediated siRNA delivery assessed in a 3D co-culture model simulating prostate cancer bone metastasis.
Fitzgerald KA; Guo J; Raftery RM; Castaño IM; Curtin CM; Gooding M; Darcy R; O' Brien FJ; O' Driscoll CM
Int J Pharm; 2016 Sep; 511(2):1058-69. PubMed ID: 27492023
[TBL] [Abstract][Full Text] [Related]
26. Image-guided prostate cancer therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide nanoparticles.
Yu MK; Kim D; Lee IH; So JS; Jeong YY; Jon S
Small; 2011 Aug; 7(15):2241-9. PubMed ID: 21648076
[TBL] [Abstract][Full Text] [Related]
27. Systemic Administration and Targeted Radiosensitization via Chemically Synthetic Aptamer-siRNA Chimeras in Human Tumor Xenografts.
Ni X; Zhang Y; Zennami K; Castanares M; Mukherjee A; Raval RR; Zhou H; DeWeese TL; Lupold SE
Mol Cancer Ther; 2015 Dec; 14(12):2797-804. PubMed ID: 26438155
[TBL] [Abstract][Full Text] [Related]
28. Successful in vivo tumor targeting of prostate-specific membrane antigen with a highly efficient J591/PEI/DNA molecular conjugate.
Moffatt S; Papasakelariou C; Wiehle S; Cristiano R
Gene Ther; 2006 May; 13(9):761-72. PubMed ID: 16453011
[TBL] [Abstract][Full Text] [Related]
29. The use of collagen-based scaffolds to simulate prostate cancer bone metastases with potential for evaluating delivery of nanoparticulate gene therapeutics.
Fitzgerald KA; Guo J; Tierney EG; Curtin CM; Malhotra M; Darcy R; O'Brien FJ; O'Driscoll CM
Biomaterials; 2015 Oct; 66():53-66. PubMed ID: 26196533
[TBL] [Abstract][Full Text] [Related]
30. Targeted chemoimmunotherapy using drug-loaded aptamer-dendrimer bioconjugates.
Lee IH; An S; Yu MK; Kwon HK; Im SH; Jon S
J Control Release; 2011 Nov; 155(3):435-41. PubMed ID: 21641946
[TBL] [Abstract][Full Text] [Related]
31. Atelocollagen-mediated intravenous siRNA delivery specific to tumor tissues orthotopically xenografted in prostates of nude mice and its anticancer effects.
Yuan Y; Makita N; Cao D; Mihara K; Kadomatsu K; Takei Y
Nucleic Acid Ther; 2015 Apr; 25(2):85-94. PubMed ID: 25692652
[TBL] [Abstract][Full Text] [Related]
32. Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer.
Mu P; Nagahara S; Makita N; Tarumi Y; Kadomatsu K; Takei Y
Int J Cancer; 2009 Dec; 125(12):2978-90. PubMed ID: 19422046
[TBL] [Abstract][Full Text] [Related]
33. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts.
Ni X; Zhang Y; Ribas J; Chowdhury WH; Castanares M; Zhang Z; Laiho M; DeWeese TL; Lupold SE
J Clin Invest; 2011 Jun; 121(6):2383-90. PubMed ID: 21555850
[TBL] [Abstract][Full Text] [Related]
34. Aptamer:toxin conjugates that specifically target prostate tumor cells.
Chu TC; Marks JW; Lavery LA; Faulkner S; Rosenblum MG; Ellington AD; Levy M
Cancer Res; 2006 Jun; 66(12):5989-92. PubMed ID: 16778167
[TBL] [Abstract][Full Text] [Related]
35. Ets1 identified as a novel molecular target of RNA aptamer selected against metastatic cells for targeted delivery of nano-formulation.
Kaur J; Tikoo K
Oncogene; 2015 Oct; 34(41):5216-28. PubMed ID: 25639877
[TBL] [Abstract][Full Text] [Related]
36. Developing Folate-Conjugated miR-34a Therapeutic for Prostate Cancer: Challenges and Promises.
Li WJ; Wang Y; Liu X; Wu S; Wang M; Turowski SG; Spernyak JA; Tracz A; Abdelaal AM; Sudarshan K; Puzanov I; Chatta G; Kasinski AL; Tang DG
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396800
[TBL] [Abstract][Full Text] [Related]
37. Formulation and Evaluation of Anisamide-Targeted Amphiphilic Cyclodextrin Nanoparticles To Promote Therapeutic Gene Silencing in a 3D Prostate Cancer Bone Metastases Model.
Evans JC; Malhotra M; Fitzgerald KA; Guo J; Cronin MF; Curtin CM; O'Brien FJ; Darcy R; O'Driscoll CM
Mol Pharm; 2017 Jan; 14(1):42-52. PubMed ID: 28043128
[TBL] [Abstract][Full Text] [Related]
38. RNA interference targeting PSCA suppresses primary tumor growth and metastasis formation of human prostate cancer xenografts in SCID mice.
Zhao Z; He J; Kang R; Zhao S; Liu L; Li F
Prostate; 2016 Feb; 76(2):184-98. PubMed ID: 26477693
[TBL] [Abstract][Full Text] [Related]
39. An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells.
Ara MN; Matsuda T; Hyodo M; Sakurai Y; Hatakeyama H; Ohga N; Hida K; Harashima H
Biomaterials; 2014 Aug; 35(25):7110-20. PubMed ID: 24875764
[TBL] [Abstract][Full Text] [Related]
40. PSMA-targeted dendrimer as an efficient anticancer drug delivery vehicle for prostate cancer.
Dhull A; Wei J; Pulukuri AJ; Rani A; Sharma R; Mesbahi N; Yoon H; Savoy EA; Xaivong Vi S; Goody KJ; Berkman CE; Wu BJ; Sharma A
Nanoscale; 2024 Mar; 16(11):5634-5652. PubMed ID: 38440933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
